EGFR and head and neck cancer: Also, pan-HER, composed of a mixture of six monoclonal antibodies targeted against EGFR, HER2,and HER3, demonstrated antiproliferative and radiosensitizing impact in human lung and head and neck cancer (Francis et al., 2016).